MAP2K7 and acute promyelocytic leukemia: Our results suggested that Sorafenib (Raf inhibitor) or U0126 (MEK inhibitor) significantly inhibited the replication of oncoVV-APL but not the others in MCF-7 cells (Figure 4a).